Use Of Specialty Drug Tiers Jumps Among Employer Plans In 2013, Survey Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The increase in the number of employer plans with four or more formulary tiers in 2013 is notable because the percentage remained in the 13% to 14% range for the past three years, according to figures from an annual survey by the Kaiser Family Foundation and the Health Research and Educational Trust.
You may also be interested in...
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.